CTAG1B and synovial sarcoma: In another phase I/II clinical trial (NCT03250325, Table 2) evaluating the safety and efficacy of novel NY‐ESO‐1‐specific TCR‐transduced T lymphocytes in synovial sarcoma patients, promising outcomes were reported.